Related content

Design of excitatory amino acid receptor agonists, partial agonists and antagonists: ibotenic acid as a key lead structure

By Krogsgaard-Larsen P.   Ebert B.   Lund T.   Brauner-Osborne H.   Slok F.   Johansen T.   Brehm L.   Madsen U.  

European Journal of Medicinal Chemistry, Vol. 31, Iss. 7, 1996-01 ,pp. : 515-537

Elsevier

Access to resources Recommend Favorite

Excitatory amino-acid receptor agonists. Synthesis and pharmacology of analogues of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid

By Slok F.   Ebert B.   Lang Y.   Krogsgaard-Larsen P.   Lenz S.   Madsen U.  

European Journal of Medicinal Chemistry, Vol. 32, Iss. 4, 1997-01 ,pp. : 329-338

Elsevier

Access to resources Recommend Favorite

The therapeutic applications of cannabinoid agonists and antagonists

By Petitet F.   Imperato A.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 39-54

Informa Healthcare

Access to resources Recommend Favorite

Interaction of ethanol with excitatory amino acid receptor antagonists in mice

By Vanover K.E.  

European Journal of Pharmacology, Vol. 368, Iss. 2, 1999-03 ,pp. : 137-142

Elsevier

Access to resources Recommend Favorite

Therapeutic potential of drugs acting on excitatory amino acid receptors

By Scatton B.   Avenet P.   Benavides J.   Besnard F.   Carter C.   Duverger D.   Graham D.   Leacute onardon J.   Santa-Maria R.   Langer S.Z.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 169-170

Elsevier

Access to resources Recommend Favorite